Having low lung function as a middle-aged smoker without airway obstruction raised the likelihood for all-cause mortality, ...

The FDA has approved Jascayd (nerandomilast) as a treatment for a second lung disease, progressive pulmonary fibrosis, following the drug’s initial approval in October 2025 as a treatment for ...

Just two months after reviving its prowess in the idiopathic pulmonary fibrosis (IPF) treatment area with rare lung disease med Jascayd, Boehringer Ingelheim is already unlocking another patient po | ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo ...

Pulmonary exacerbations are common in children with cystic fibrosis during the first 3 years of life and are associated with ...

Here are the top 5 most-read pulmonary fibrosis articles of 2025.

Please provide your email address to receive an email when new articles are posted on . A smartphone-based tool that employs acoustic sensing and machine learning techniques is set to undergo testing.

The use of inhaled corticosteroids during pregnancy may protect against reduced lung function in infants born to mothers with ...

Exciting news for those affected by progressive pulmonary fibrosis (PPF): The US FDA has granted approval for Jascayd (nerandomilast). This groundbreaking medication goes beyond merely alleviating ...

A 40-year-old woman who was a frequent traveler suddenly found herself struggling to breathe after taking just a few steps. What began as unexplained fatigue and shortness of breath quickly disrupted ...

Pulmonary diagnostic tests are a series of tests which evaluate how well the lungs are performing. These tests may be performed to help diagnose disease, monitor disease progression or therapeutic ...